| Document and Entity Information | 3 Months Ended |
| Jun. 30, 2016shares | |
| Document and Entity Information: | |
| Entity Registrant Name | Lotus Biotech Development Corp. |
| Document Type | 10-Q |
| Document Period End Date | Jun. 30, 2016 |
| Amendment Flag | false |
| Entity Central Index Key | 1,520,592 |
| Current Fiscal Year End Date | --03-31 |
| Entity Common Stock, Shares Outstanding | 82,775,000 |
| Entity Filer Category | Smaller Reporting Company |
| Entity Current Reporting Status | No |
| Entity Voluntary Filers | No |
| Entity Well-known Seasoned Issuer | No |
| Document Fiscal Year Focus | 2,017 |
| Document Fiscal Period Focus | Q1 |
| Trading Symbol | lbtd |
| LOTUS BIO-TECHNOLOGY DEVELOPMENT CORP. - Balance Sheets - USD ($) | Jun. 30, 2016 | Mar. 31, 2015 | |
| Current Assets: | |||
| Cash and cash equivalents | $ 1 | $ 5 | |
| Total Current Assets | 1 | 5 | |
| Capital Assets: | |||
| Property and equipment, net | 4,912 | 5,458 | |
| Total capital assets | 4,912 | 5,458 | |
| TOTAL ASSETS | 4,913 | 5,463 | |
| Current liabilities: | |||
| Accounts payable and accrued liabilities | 16,277 | 15,313 | |
| Due to related party | 51,454 | 51,458 | |
| Total Current Liabilities | 67,731 | 66,771 | |
| TOTAL LIABILITIES | 67,731 | 66,771 | |
| Stockholders' Deficit | |||
| Preferred stock | [1] | ||
| Common stock | [2] | 828 | 828 |
| Additional paid-in capital | 867,263 | 867,263 | |
| Accumulated deficit | (930,909) | (929,399) | |
| TOTAL STOCKHOLDERS' DEFICIT | (62,818) | (61,308) | |
| TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | $ 4,913 | $ 5,463 | |
| [1] | 100,000,000 authorized, par value $0.00001, nil issued and outstanding. | ||
| [2] | 300,000,000 authorized, par value $0.00001, 82,775,000 issued and outstanding. | ||
| LOTUS BIO-TECHNOLOGY DEVELOPMENT CORP. - Balance Sheets, Parenthetical - $ / shares | Jun. 30, 2016 | Mar. 31, 2016 |
| Statement of Financial Position | ||
| Common Stock, Par Value | $ 0.00001 | $ 0.00001 |
| Common Stock, Shares Authorized | 300,000,000 | 300,000,000 |
| Common Stock, Shares Issued | 82,775,000 | 82,775,000 |
| Common Stock, Shares Outstanding | 82,775,000 | 82,775,000 |
| Preferred Stock, Par Value | $ 0.00001 | $ 0.00001 |
| Preferred Stock, Shares Authorized | 100,000,000 | 100,000,000 |
| Preferred Stock, Shares Issued | ||
| Preferred Stock, Shares Outstanding |
| LOTUS BIO-TECHNOLOGY DEVELOPMENT CORP. - Statements of Operations - USD ($) | 3 Months Ended | |
| Jun. 30, 2016 | Jun. 30, 2015 | |
| Expenses | ||
| Accounting and legal | $ 501 | $ 1,408 |
| General and administrative | 20 | |
| Stock transfer management | 443 | 745 |
| Amortization expense | 546 | |
| Total operating expenses | 1,510 | 2,153 |
| Loss from operations | (1,510) | (2,153) |
| Net loss | $ (1,510) | $ (2,153) |
| Basic and diluted net loss per common share | $ 0 | $ 0 |
| Weighted average number of common shares outstanding, basic and diluted | 82,775,000 | 181,275,000 |
| LOTUS BIO-TECHNOLOGY DEVELOPMENT CORP. - Statements of Cash Flows - USD ($) | 3 Months Ended | |
| Jun. 30, 2016 | Jun. 30, 2015 | |
| Cash flows from operating activities: | ||
| Net loss | $ (1,510) | $ (2,153) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Amortization expense | 546 | |
| Changes in operating assets and liabilities | ||
| Accounts payable and accrued liabilities, increase decrease | 964 | (2,492) |
| Net cash used in operating activities | (4,645) | |
| Cash flows from financing activities | ||
| Net borrowings (repayments) to related party | (4) | 3,141 |
| Net cash provided by (used in) financing activities | (4) | 3,141 |
| Net decrease in cash and cash equivalents | (4) | (1,504) |
| Cash and cash equivalents, beginning of period | 5 | 1,505 |
| Cash and cash equivalents, end of period | 1 | 1 |
| Supplemental Cash Flow Information | ||
| Cash paid for interest | ||
| Cash paid for income taxes | ||
| 1. Description of Business and Basis of Presentation | 3 Months Ended |
| Jun. 30, 2016 | |
| Notes | |
| 1. Description of Business and Basis of Presentation | 1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Lotus Bio-Technology Development Corp (we, our, the Company) was formed on March 24, 2011 with planned principal operations as an independent motion picture producer. In 2016, the Company has shifted its focus and began exploring opportunities in the organic growth and farming sector in China. In May of 2016, the Company has changed its name, president and business direction and entered into the organic bio development space. On May 7 th The accompanying unaudited interim financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information required to be included in a complete set of financial statements in accordance with accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended June 30, 2016 are not necessarily indicative of the results that may be expected for the fiscal year ending March 31, 2017. The accompanying unaudited financial statements should be read in conjunction with the financial statements and related notes included in the Company's March 31, 2016 Form 10-K. |
| 2. Going Concern | 3 Months Ended |
| Jun. 30, 2016 | |
| Notes | |
| 2. Going Concern | 2. GOING CONCERN The Companys interim unaudited financial statements are prepared using generally accepted accounting principles applicable to a going concern which contemplates realization of assets and liquidation of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has incurred net loss of $1,510 for the three months ended June 30, 2016. The Company has not generated any operating revenues to date, has a working capital deficit and existence is dependent upon managements ability to develop profitable operations. These conditions raise substantial doubt that the Company will be able to continue as a going concern. These financial statements do not include any adjustments that might result from this uncertainty. Our activities to date have been supported by equity financing and demand loans from our major shareholder. Management continues to seek funding from its shareholders and other qualified investors to pursue its business plan and new course of action. |
| 3. Due To Related Party | 3 Months Ended |
| Jun. 30, 2016 | |
| Notes | |
| 3. Due To Related Party | 3. DUE TO RELATED PARTY As at June 30, 2016 the balance due to a majority shareholder was $51,454 .The amount due to the major shareholder is unsecured, non-interest bearing and due on demand. |
| 4. Subsequent Events | 3 Months Ended |
| Jun. 30, 2016 | |
| Notes | |
| 4. Subsequent Events | 4. SUBSEQUENT EVENTS On August 5, 2016 there was an advance of $6,450 from current president to the company. The advance is non secured, non-interest bearing and due on demand . |
| 3. Due To Related Party (Details) | Jun. 30, 2016USD ($) |
| Details | |
| Due to Officers or Stockholders, Current | $ 51,454 |
| 4. Subsequent Events (Details) | Aug. 05, 2016USD ($) |
| Details | |
| Advances to Affiliate | $ 6,450 |
